ADVERTORIAL
In addition, continuous flow chemistry expands the chemical toolbox with higher temperature and pressure windows. The broadened processing window, together with the decreased risk from hazardous reagents, enables shorter synthetic reaction schemes and improves the purity and yield of certain reactions. In addition, flow processes have lower production costs due to the smaller footprint and decreased energy consumption.
Continuous flow also makes it possible to use alternative forms of energy to promote chemical reaction, such as electricity and light. Scale-up remained an engineering hurdle but Creaflow’ s and Ajinomoto Bio-Pharma Services recently co-developed multi-purpose HANU ' s photoreactor has overcome this.
Focus on speed
Continuous manufacturing can significantly contribute to speeding up product development. Depending on the required volumes, a continuous flow installation can be used to make larger amounts simply by running the set-up for longer, a process often called scaling-out.
Furthermore, the scale-up of continuous processes is often straightforward and both footprint and capital expenditures are lower than batch. As a consequence, commissioning a novel continuous flow reactor train is markedly faster than that of a new batch chemistry unit. ●
References: 1: Org. Process Res. Dev., 2018, 22( 9), 1143-1166, DOI: 10.1021 / acs. oprd. 8b00160 2: https:// www. fda. gov / regulatory-information / search-fdaguidancedocuments / qualityconsiderations-continuousmanufacturing 3: ChemSusChem. 2013,
J j
AJINOMOTO BIO-PHARMA SERVICES
info @ US. AjiBio-Pharma. com www. AjiBio-Pharma. com
About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated CDMO. Its sites in Belgium, India, Japan and the US provide comprehensive process development services, cGMP manufacturing of small molecule, oligonucleotide and peptide APIs and intermediates.
Ajinomoto Bio-Pharma offers a broad range of innovative platforms and capabilities to scale rapidly from clinical and pilot programs to commercial volumes, including: high potency APIs( HPAPIs), biocatalysis and continuous flow manufacturing, oligonucleotide & peptide synthesis, and our technology platforms Ajiphase Corynex and Talamax.
The business has made significant investments in to its continuous flow equipment and technical staff. It implements or develops new equipment to continuously improve processes or tackle customers’ scale-up issues. This includes slurry-compatible plug-flow reactors, immiscible-liquids reaction scale-up, inline degassers, counter-current extractors and the HANU flow reactor.
Ajinomoto Bio-Pharma’ s centre of excellence in continuous flow in Belgium serves a global customer base. It boasts a wealth of expertise in HPAPIs and complex chemistries. Its small molecule manufacturing capabilities are based on decades of experience, from hydride reduction to enzymatic conversion, organometallic, cryogenic and oxidation chemistries, energetic reactions, catalytic hydrogenation, plus various other complex, toxic, and potent chemistries.
To maximise the advantages achieved by continuous flow processing, Ajinomoto Bio-Pharma has invested heavily in its laboratory capabilities with new modular set-ups, including reactors, automated pumps, and other novel equipment like its photoflow reactor and high temperature reactor; in PAT, such as Raman spectroscopy; and in extraction equipment, including membrane-assisted phase separators, mixers and settlers.
The insights gained through conducting scale-up studies, continuous improvement projects and feasibility testing to improve the sustainability and economics of applications have resulted in other equipment investments, such as Chemtrix scalable flow reactors and tubular flow reactors developed in-house.
38 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981